Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: A review of controlled trials

Journal of Nephrology

Volumn 21, Issue 3, 2008, Pages 374-383

  Segall, Liviu ^a   Oprisiu, Roxana ^b   Fournier, Albert ^b   Covic, Adrian ^a  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

ACE inhibitors; Cardiovascular disease; Chronic kidney disease; Diuretics; Hypertension

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; EVENING DOSAGE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; META ANALYSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; CHRONIC DISEASE; KIDNEY DISEASE; RANDOMIZED CONTROLLED TRIAL; STROKE;

ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 52049089966     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Garcia-Castrillo L. Stroke care in Europe: emergency medicine role. Foundation for the Education and Research in Neurological Emergencies (FERNE). Available at: http://www.uic.edu/com/ferne/pdf/aaem2003/ reisgostrokeaaem0903.pdf. Accessed March 18, 2008.
2. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
3. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003;64:610-615.
4. Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology. 2006;67:224-228.
5. Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264-1271.
6. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: a possible marker of increased risk of stroke. Stroke. 1997;28:557-563.
7. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension. 2001;37:1069-1074.
8. Guerrero-Romero F, Rodriguez-Moran M. Proteinuria is an independent risk factor for ischemic stroke in non-insulin-dependent diabetes mellitus. Stroke. 1999;30:1787-1791.
9. Madison JR, Spies C, Schatz IJ, et al. Proteinuria and risk for stroke and coronary heart disease during 27 years of follow-up. The Honolulu Heart Program. Arch Intern Med. 2006;166:884-889.
10. Seliger SL, Siscovick DS, Stehman-Breen CO, et al. Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. J Am Soc Nephrol. 2004;15:1904-1911.
11. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005;16:489-495.
12. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377-1384.
13. Stegmayr BG, Brännström M, Bucht S, et al; for the Nediat study group. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scand J Urol Nephrol. 2005;39:489-497.
14. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
15. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386-392.
16. Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35:1024-1033.
17. Staessen JA, Li Y, Thijs L, Wang J-G. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28:385-407.
18. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
19. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study investigators. N Engl J Med. 2000;342:145-153.
20. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
21. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
22. PATS collaborating group. Post-stroke Antihypertensive Study. Chin Med J. 1995;108:710-717.
23. Svensson P, de Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressures: HOPE substudy. Hypertension. 2001;38:28-32.
24. Omama S, Yoshida Y, Ogawa A, Onoda T, Okayama A. Differences in circadian variation of cerebral infarction, intracerebral haemorrhage and subarachnoid haemorrhage by situation at onset. J Neurol Neurosurg Psychiatry. 2006;77:1345-1349.
25. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin. 2004;20:1559-1569.
26. Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation. 2001;103:919-925.
27. Fournier A, Oprisiu R, Andrejak M, Godefroy O, Rosa A, Achard J-M. Age-adjusted stroke incidence increase: could angiotensin AT1 receptor antagonists enhance stroke prevention? Stroke. 2002;33:881-882.
28. Papademetriou V, Farsang C, Elmfeldt D, et al; Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44:1175-1180.
29. Dahlöf B, Devereux RB, Kjeldsen SE, et al; for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
30. Schrader J, Lüders S, Kulschewski A, et al; for the MOSES study group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36:1218-1226.
31. Julius S, Kjeldsen SE, Weber M, et al; for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the VALUE randomised trial. Lancet. 2004;363:2022-2031.
32. Oprisiu R, Serot J-M, Shahapuni I, Mansour J, Boutitie F, Fournier A. Indirect comparison by a common comparator of angiotensin receptor type 1 blocker (AT1RB) with ACE inhibitor (ACEI) in stroke prevention. Int J Stroke. 2006;1(suppl 1):3-46.
33. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
34. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARBMI paradox. Circulation. 2006;114:838-854.
35. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol. 2004;43:1343-1347.
36. Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465-471.
37. Teo K, Yusuf S, Sleight P, et al; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52-61.
38. Pahor M, Shorr RI, Somes GW, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the Systolic Hypertension in the Elderly Program. Arch Intern Med. 1998;158:1340-1345.
39. Perkovic V, Algert C, Arima H, et al. Reductions in the risks of vascular events and stroke in patients with and without chronic kidney disease: new data from the PROGRESS trial [abstract]. Australia and New Zealand Society of Nephrology and Renal Society of Australasia 2006 annual scientific conference, Melbourne, Australia, 14-19 August 2006. Available at: http://www.icms.com.au/anzsn2006/abstract/193.htm. Accessed March 18, 2008.
40. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S; for the HOPE Investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-636.
41. The PEACE Trial Investigators. Angiotensin-convertingenzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
42. Marre M, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J; on behalf of the DIABHYCAR study investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ. 2004;328;495-501.
43. Brenner B. Reduction of endpoints in non-insulin-dependent diabetes mellitus with angiotensin II antagonist losartan [abstract]. 16th annual meeting of the American Society of Hypertension, San Francisco, CA, 16-19 May, 2001.
44. Berl T, Hunsicker LG, Lewis JB, et al; for the Collaborative Study Group. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542-549.
45. Rahman M, Pressel S, Davis BR, et al; for the ALLHAT Collaborative Research Group. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med. 2006;144:172-180.
46. Norris K, Bourgoigne J, Gassman J, et al; for the AASK Study Group. Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial. Am J Kidney Dis. 2006;48:739-751.
47. Ibsen H, Olsen MH, Wachtell K, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care. 2006;29:595-600.
48. Nakamura T, Kanno Y, Takenaka T, Suzuki H; for the Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res. 2005;28:415-423.
49. Solomon SD, Rice MM, Gersh BJ, et al; for the Prevention of Events with ACE inhibition (PEACE) investigators. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114:26-31.
50. Suzuki H, Kanno Y; for the Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res. 2005;28:307-314.
51. Guyton AC. Kidneys and fluids in pressure regulation: small volume but large pressure changes. Hypertension. 1992;19(1 suppl):I2-I8.